⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12217234 | 0.85 | — | — | |
| SCHEMBL17075357 | 0.80 | — | — | |
| SCHEMBL8852299 | 0.74 | — | — | |
| SCHEMBL10977788 | 0.67 | NPC1 (0.35) | — | |
| SCHEMBL17257634 | 0.64 | — | — | |
| SCHEMBL10981130 | 0.63 | NPC1 (0.33) | — | |
| SCHEMBL3289230 | 0.59 | — | — | |
| Hydrochloric Acid SCHEMBL10840793 | 0.58 | — | — | |
| SCHEMBL31290680 | 0.58 | — | — | |
| SCHEMBL7356485 | 0.58 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 56 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240226113-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | KUMQUAT BIOSCIENCES INC. | 2024-07-11 | — | — | US | disclosed |
| EP-4327809-A2 | TYK2 INHIBITORS AND USES THEREOF | Takeda Pharmaceutical Company Limited (JP) | 2024-02-28 | — | — | EP | disclosed |
| US-20240025879-A1 | PYRIDAZINONE COMPOUNDS AND USES THEREOF | EDGEWISE THERAPEUTICS, INC. | 2024-01-25 | — | — | US | disclosed |
| WO-2023083343-A1 | POLYCYCLIC COMPOUNDS AND METHODS THEREOF | HEPAITECH (BEIJING) BIOPHARMA TECHNOLOGY CO., LTD. (CN) | 2023-05-19 | — | — | WO | disclosed |
| WO-2022190632-A1 | ANIMAL REPELLING COMPOSITION AND ANIMAL REPELLING METHOD | 株式会社カネカ | 2022-09-15 | — | — | WO | disclosed |
| WO-2022190633-A1 | ANIMAL REPELLING DEVICE AND ANIMAL REPELLING METHOD | 株式会社カネカ | 2022-09-15 | — | — | WO | disclosed |
| US-20220073527-A1 | TYK2 INHIBITORS AND USES THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2022-03-10 | — | — | US | disclosed |
| US-11149034-B2 | Derivatives of luciferin and methods for their synthesis | UNIVERSITY OF CAPE TOWN (ZA) | 2021-10-19 | — | — | US | disclosed |
| EP-3848370-A2 | TYK2 INHIBITORS AND USES THEREOF | Nimbus Lakshmi, Inc. (US) | 2021-07-14 | — | — | EP | disclosed |
| EP-2534949-B1 | ANIMAL REPELLENT | SCENT SCIENCE INT INC (JP) | 2021-06-02 | — | — | EP | disclosed |
| US-7871982-B2 | Lincomycin derivatives and antimicrobial agents comprising the same as active ingredient | MEIJI SEIKA KAISHA, LTD. (JP) | 2011-01-18 | — | — | US | disclosed |
| US-20100256092-A1 | BORON-CONTAINING SMALL MOLECULES | ANACOR PHARMACEUTICALS, INC. (US) | 2010-10-07 | — | — | US | disclosed |
| US-20090227588-A1 | Substituted pyrazole compounds useful as soluble epoxide hyrolase inhibitors | FLECK ROMAN WOLFGANG | 2009-09-10 | — | — | US | disclosed |
| US-20090163549-A1 | Pharmaceutical Composition Comprising an Amide Derivative | SHIONOGI & CO., LTD. (JP) | 2009-06-25 | — | — | US | disclosed |
| US-20090156512-A1 | potent activity against resistant pneumococci | MEIJI SEIKA KAISHA, LTD. (JP) | 2009-06-18 | — | — | US | disclosed |
| US-7459450-B2 | Neuropeptide receptor modulators | SCHERING CORPORATION (US) | 2008-12-02 | — | — | US | disclosed |
| WO-2008143729-A2 | MACROLIDE COMPOUNDS AND METHODS OF MAKING AND USING THE SAME | RIB-X PHARMACEUTICALS, INC. (US) | 2008-11-27 | — | — | WO | disclosed |
| US-7262200-B2 | Indazolinone compositions useful as kinase inhibitors | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2007-08-28 | — | — | US | disclosed |
| WO-2007084450-A2 | CANNIBINOID RECEPTOR MODULATORS | SCHERING CORPORATION (US) | 2007-07-26 | — | — | WO | disclosed |
| US-7173129-B2 | Sulfonamide-substituted chalcone derivatives and their use to treat diseases | ATHERO GENICS, INC. (US) | 2007-02-06 | — | — | US | disclosed |